OncoMatch/Clinical Trials/NCT06172595
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
Is NCT06172595 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for glioma, malignant.
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\[18F\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of \[18F\]FET-PET in delineating disease. The main question\[s\] it aims to answer are: * whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression * whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Disease stage
Required: Stage WHO GRADE III, WHO GRADE IV (WHO)
Excluded: Stage WHO GRADE I, WHO GRADE II
malignant glioma (defined as WHO grade III or IV); Low-grade gliomas (histology grade 1 or 2 by WHO classification) [excluded]
Prior therapy
Must have received: radiation therapy
previous RT to tumour
Cannot have received: vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments (bevacizumab)
Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify